Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Immunotherapies have revolutionized medical oncology following the remarkable and, in
some cases, unprecedented outcomes observed in certain groups of patients with cancer …
some cases, unprecedented outcomes observed in certain groups of patients with cancer …
Chemotherapeutic drug-induced immunogenic cell death for nanomedicine-based cancer chemo–immunotherapy
M Jiang, J Zeng, L Zhao, M Zhang, J Ma, X Guan… - Nanoscale, 2021 - pubs.rsc.org
Chemotherapy has been a conventional paradigm for cancer treatment, and multifarious
chemotherapeutic drugs have been widely employed for decades with significant …
chemotherapeutic drugs have been widely employed for decades with significant …
Combining immunotherapy and targeted therapies in cancer treatment
M Vanneman, G Dranoff - Nature reviews cancer, 2012 - nature.com
During the past two decades, the paradigm for cancer treatment has evolved from relatively
nonspecific cytotoxic agents to selective, mechanism-based therapeutics. Cancer …
nonspecific cytotoxic agents to selective, mechanism-based therapeutics. Cancer …
[HTML][HTML] Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma
K Shigeta, A Matsui, H Kikuchi, S Klein… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background and purpose Combining inhibitors of vascular endothelial growth factor and the
programmed cell death protein 1 (PD1) pathway has shown efficacy in multiple cancers, but …
programmed cell death protein 1 (PD1) pathway has shown efficacy in multiple cancers, but …
[HTML][HTML] Nanoliposome C6-ceramide increases the anti-tumor immune response and slows growth of liver tumors in mice
Background & Aims Ceramide, a sphingolipid metabolite, affects T-cell signaling, induces
apoptosis of cancer cells, and slows tumor growth in mice. However, it has not been used as …
apoptosis of cancer cells, and slows tumor growth in mice. However, it has not been used as …
[HTML][HTML] STAT proteins–key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver
Since its discovery in the early 1990s, the Janus kinase (JAK)-signal transducer and
activator of transcription (STAT) signaling pathway has been found to play key roles in …
activator of transcription (STAT) signaling pathway has been found to play key roles in …
Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma
Objective Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer
with limited treatment options. Cabozantinib, an orally bioavailable multikinase inhibitor is …
with limited treatment options. Cabozantinib, an orally bioavailable multikinase inhibitor is …
[HTML][HTML] Mouse models of liver cancer: Progress and recommendations
L He, DA Tian, PY Li, XX He - Oncotarget, 2015 - ncbi.nlm.nih.gov
To clarify the pathogenesis of hepatocellular carcinoma (HCC) and investigate the effects of
potential therapies, a number of mouse models have been developed. Subcutaneous …
potential therapies, a number of mouse models have been developed. Subcutaneous …
Immunotherapy of hepatocellular carcinoma: unique challenges and clinical opportunities
AD Pardee, LH Butterfield - Oncoimmunology, 2012 - Taylor & Francis
Current therapies for advanced hepatocellular carcinoma (HCC) are marginally effective
and exacerbate underlying liver disease. The ability of immunotherapy to elicit nontoxic …
and exacerbate underlying liver disease. The ability of immunotherapy to elicit nontoxic …
[HTML][HTML] Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response
Background Minimally invasive radiofrequency ablation (RFA) is used as a first-line
treatment option for hepatocellular cancer (HCC) with the weaknesses of incomplete …
treatment option for hepatocellular cancer (HCC) with the weaknesses of incomplete …